{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:19:42Z","timestamp":1777702782210,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T00:00:00Z","timestamp":1525478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00592-018-1151-x","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T07:26:07Z","timestamp":1525505167000},"page":"789-796","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":118,"title":["Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema"],"prefix":"10.1007","volume":"55","author":[{"name":"For the International Retina Group","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6267-4663","authenticated-orcid":false,"given":"Catharina","family":"Busch","sequence":"first","affiliation":[]},{"given":"Dinah","family":"Zur","sequence":"additional","affiliation":[]},{"given":"Samantha","family":"Fraser-Bell","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"La\u00edns","sequence":"additional","affiliation":[]},{"given":"Ana Rita","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Lupidi","sequence":"additional","affiliation":[]},{"given":"Carlo","family":"Cagini","sequence":"additional","affiliation":[]},{"given":"Pierre-Henry","family":"Gabrielle","sequence":"additional","affiliation":[]},{"given":"Aude","family":"Couturier","sequence":"additional","affiliation":[]},{"given":"Val\u00e9rie","family":"Man\u00e9-Tauty","sequence":"additional","affiliation":[]},{"given":"Ermete","family":"Giancipoli","sequence":"additional","affiliation":[]},{"given":"Giuseppe D\u2019Amico","family":"Ricci","sequence":"additional","affiliation":[]},{"given":"Zafer","family":"Cebeci","sequence":"additional","affiliation":[]},{"given":"Patricio J.","family":"Rodr\u00edguez-Vald\u00e9s","sequence":"additional","affiliation":[]},{"given":"Voraporn","family":"Chaikitmongkol","sequence":"additional","affiliation":[]},{"given":"Atchara","family":"Amphornphruet","sequence":"additional","affiliation":[]},{"given":"Isaac","family":"Hindi","sequence":"additional","affiliation":[]},{"given":"Kushal","family":"Agrawal","sequence":"additional","affiliation":[]},{"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[]},{"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[]},{"given":"Matias","family":"Iglicki","sequence":"additional","affiliation":[]},{"given":"Matus","family":"Rehak","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,5,5]]},"reference":[{"issue":"6","key":"1151_CR1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00592-017-0984-z","volume":"54","author":"AI Arroba","year":"2017","unstructured":"Arroba AI, Valverde AM (2017) Modulation of microglia in the retina: new insights into diabetic retinopathy. Acta Diabetol 54(6):527\u2013533. \n                    https:\/\/doi.org\/10.1007\/s00592-017-0984-z\n                    \n                  \u00a0","journal-title":"Acta Diabetol"},{"issue":"3","key":"1151_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JW Yau","year":"2012","unstructured":"Yau JW, Rogers SL, Kawasaki R et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35(3):556\u2013564. \n                    https:\/\/doi.org\/10.2337\/dc11-1909\n                    \n                  \u00a0","journal-title":"Diabetes Care"},{"issue":"11","key":"1151_CR3","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/j.ophtha.2009.04.023","volume":"116","author":"QD Nguyen","year":"2009","unstructured":"Nguyen QD, Shah SM, Heier JS et al (2009) Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 116(11):2175\u20132181. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2009.04.023\n                    \n                  \u00a0","journal-title":"Ophthalmology"},{"issue":"13","key":"1151_CR4","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR et al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372(13):1193\u20131203. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1414264","journal-title":"N Engl J Med"},{"issue":"12","key":"1151_CR5","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/j.ophtha.2014.07.002","volume":"121","author":"MC Gillies","year":"2014","unstructured":"Gillies MC, Lim LL, Campain A et al (2014) A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology 121(12):2473\u20132481. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.002\n                    \n                  \u00a0","journal-title":"Ophthalmology"},{"issue":"10","key":"1151_CR6","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"DS Boyer","year":"2014","unstructured":"Boyer DS, Yoon YH, Belfort R Jr et al (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121(10):1904\u20131914. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2014.04.024\n                    \n                  \u00a0","journal-title":"Ophthalmology"},{"issue":"12","key":"1151_CR7","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1136\/bjophthalmol-2017-310242","volume":"101","author":"MV Cicinelli","year":"2017","unstructured":"Cicinelli MV, Cavalleri M, Querques L, Rabiolo A, Bandello F, Querques G (2017) Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema. Br J Ophthalmol 101(12):1689\u20131693. \n                    https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310242\n                    \n                  \u00a0","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"1151_CR8","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.18240\/ijo.2016.10.10","volume":"9","author":"F Pacella","year":"2016","unstructured":"Pacella F, Romano MR, Turchetti P et al (2016) An eighteen-month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy. Int J Ophthalmol 9(10):1427\u20131432. \n                    https:\/\/doi.org\/10.18240\/ijo.2016.10.10","journal-title":"Int J Ophthalmol"},{"issue":"6","key":"1151_CR9","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ophtha.2015.12.012","volume":"123","author":"S Fraser-Bell","year":"2016","unstructured":"Fraser-Bell S, Lim LL, Campain A et al (2016) Bevacizumab or dexamethasone implants for DME: 2-year results (the BEVORDEX study). Ophthalmology 123(6):1399\u20131401. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2015.12.012\n                    \n                  \u00a0","journal-title":"Ophthalmology"},{"issue":"7","key":"1151_CR10","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.ophtha.2015.03.024","volume":"122","author":"A Das","year":"2015","unstructured":"Das A, McGuire PG, Rangasamy S (2015) Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology 122(7):1375\u20131394. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2015.03.024","journal-title":"Ophthalmology"},{"issue":"3","key":"1151_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1517\/14712598.2016.1131265","volume":"16","author":"RM Hussain","year":"2016","unstructured":"Hussain RM, Ciulla TA (2016) Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opin Biol Ther 16(3):365\u2013374. \n                    https:\/\/doi.org\/10.1517\/14712598.2016.1131265\n                    \n                  \u00a0","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"1151_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F et al (2017) Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica 237(4):185\u2013222. \n                    https:\/\/doi.org\/10.1159\/000458539\n                    \n                  \u00a0","journal-title":"Ophthalmologica"},{"key":"1151_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ajo.2016.09.012","volume":"172","author":"VH Gonzalez","year":"2016","unstructured":"Gonzalez VH, Campbell J, Holekamp NM et al (2016) Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol 172:72\u201379. \n                    https:\/\/doi.org\/10.1016\/j.ajo.2016.09.01\n                    \n                  \u00a0","journal-title":"Am J Ophthalmol"},{"key":"1151_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-310737","author":"H Mehta","year":"2017","unstructured":"Mehta H, Fraser-Bell S, Nguyen V, Lim LL, Gillies MC (2017) Short-term vision gains at 12\u00a0weeks correlate with long-term vision gains at 2\u00a0years: results from the BEVORDEX randomised clinical trial of bevacizumab versus dexamethasone implants for diabetic macular oedema. Br J Ophthalmol. \n                    https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310737\n                    \n                  \u00a0","journal-title":"Br J Ophthalmol"},{"issue":"13","key":"1151_CR15","doi-asserted-by":"publisher","first-page":"8154","DOI":"10.1167\/iovs.12-10290","volume":"53","author":"KV Chalam","year":"2012","unstructured":"Chalam KV, Bressler SB, Edwards AR et al (2012) Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography. Investig Ophthalmol Vis Sci 53(13):8154\u20138161. \n                    https:\/\/doi.org\/10.1167\/iovs.12-10290\n                    \n                  \u00a0","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"6","key":"1151_CR16","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ajo.2010.06.025","volume":"150","author":"A Giani","year":"2010","unstructured":"Giani A, Cigada M, Choudhry N et al (2010) Reproducibility of retinal thickness measurements on normal and pathologic eyes by different optical coherence tomography instruments. Am J Ophthalmol 150(6):815\u2013824. \n                    https:\/\/doi.org\/10.1016\/j.ajo.2010.06.02\n                    \n                  \u00a0","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1151_CR17","first-page":"627","volume":"4","author":"K Hajian-Tilaki","year":"2013","unstructured":"Hajian-Tilaki K (2013) Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Casp J Intern Med 4(2):627\u2013635","journal-title":"Casp J Intern Med"},{"issue":"3","key":"1151_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000356413","volume":"231","author":"M Dutra Medeiros","year":"2014","unstructured":"Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumi J, Mateo C, Corcostegui B (2014) Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica 231(3):141\u2013146. \n                    https:\/\/doi.org\/10.1159\/000356413\n                    \n                  \u00a0","journal-title":"Ophthalmologica"},{"issue":"8","key":"1151_CR19","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1097\/IAE.0000000000000533","volume":"35","author":"RK Maturi","year":"2015","unstructured":"Maturi RK, Bleau L, Saunders J, Mubasher M, Stewart MW (2015) A 12-month, single-masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti-VEGF injections to assess the efficacy of the dexamethasone-delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy. Retina 35(8):1604\u20131614. \n                    https:\/\/doi.org\/10.1097\/IAE.0000000000000533\n                    \n                  \u00a0","journal-title":"Retina"},{"issue":"1","key":"1151_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamaophthalmol.2017.4914","volume":"136","author":"RK Maturi","year":"2018","unstructured":"Maturi RK, Glassman AR, Liu D et al (2018) Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmol 136(1):29\u201338. \n                    https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.4914\n                    \n                  \u00a0","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"1151_CR21","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1097\/IAE.0000000000001038","volume":"36","author":"SU Shah","year":"2016","unstructured":"Shah SU, Harless A, Bleau L, Maturi RK (2016) Prospective randomized subject-masked study of intravitreal bevacizumab monotherapy versus dexamethasone implant monotherapy in the treatment of persistent diabetic macular edema. Retina 36(10):1986\u20131996. \n                    https:\/\/doi.org\/10.1097\/IAE.0000000000001038","journal-title":"Retina"},{"issue":"6","key":"1151_CR22","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s13300-017-0332-x","volume":"8","author":"I Chatziralli","year":"2017","unstructured":"Chatziralli I, Theodossiadis P, Parikakis E et al (2017) Dexamethasone intravitreal implant in diabetic macular edema: real-life data from a prospective study and predictive factors for visual outcome. Diabetes Ther 8(6):1393\u20131404. \n                    https:\/\/doi.org\/10.1007\/s13300-017-0332-x\n                    \n                  \u00a0","journal-title":"Diabetes Ther"},{"issue":"11","key":"1151_CR23","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1038\/eye.2017.111","volume":"31","author":"I Chatziralli","year":"2017","unstructured":"Chatziralli I, Santarelli M, Patrao N et al (2017) Identification of time point to best define \u2018sub-optimal response\u2019 following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data. Eye 31(11):1594\u20131599. \n                    https:\/\/doi.org\/10.1038\/eye.2017.111\n                    \n                  \u00a0","journal-title":"Eye"},{"key":"1151_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.08.031","author":"D Zur","year":"2017","unstructured":"Zur D, Iglicki M, Busch C et al (2017) Optical coherence tomography biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. Ophthalmology. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2017.08.031","journal-title":"Ophthalmology"},{"key":"1151_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-018-1117-z","author":"M Iglicki","year":"2018","unstructured":"Iglicki M, Zur D, Busch C, Okada M, Loewenstein A (2018) Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the \u2018DR-Pro-DEX Study\u2019. Acta Diabetol. \n                    https:\/\/doi.org\/10.1007\/s00592-018-1117-z\n                    \n                  \u00a0","journal-title":"Acta Diabetol"},{"key":"1151_CR26","doi-asserted-by":"publisher","unstructured":"Iglicki M, Busch C, Zur D, et al. (2018) Dexamethasone implant for diabetic macular edeme in naive compared with refactory eyes: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study. \n                    https:\/\/doi.org\/10.1097\/IAE.0000000000002196","DOI":"10.1097\/IAE.0000000000002196"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-018-1151-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-018-1151-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-018-1151-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T14:25:17Z","timestamp":1557152717000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-018-1151-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,5]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["1151"],"URL":"https:\/\/doi.org\/10.1007\/s00592-018-1151-x","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,5]]},"assertion":[{"value":"12 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional review board (IRB) approval was obtained through the individual IRBs at the participating institutes for a retro-spectiveconsecutive chart review. The research adhered to the tenets the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The Statement of human and animal rights in this article is not correct, because it does contain studies with human subjects performed by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}